Form 4: Liquidia Corp Chief Medical Officer Reports Routine Equity Transactions and Tax-Related Stock Sale

Liquidia Corp's Chief Medical Officer, Rajeev Saggar, reported the conversion of performance stock units into common stock and a subsequent sale of shares to cover tax obligations, executed under a pre-arranged trading plan.

Summary

• Rajeev Saggar, Chief Medical Officer of Liquidia Corp (LQDA), reported transactions involving company equity.
• On July 11, 2025, 3,531 Performance Stock Units (PSUs) converted into common stock.
• On July 14, 2025, 5,327 shares of common stock were sold at a price of $14.28 per share.
• The sale was executed pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.
• The purpose of the share sale was to cover taxes associated with the settlement of previously granted Restricted Stock Units (RSUs) and PSUs from January 11, 2023, and January 11, 2024, grants.
• Following these transactions, Rajeev Saggar's direct beneficial ownership of Liquidia Corp common stock is 271,413 shares.
• This beneficial ownership includes 5,865 unvested RSUs from a July 18, 2022 grant, 31,249 unvested RSUs from a January 11, 2023 grant, 35,307 unvested RSUs from a January 11, 2024 grant, and 71,780 unvested RSUs from a January 11, 2025 grant.
• The total also includes 6,291 shares of common stock acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.
• Of the 56,492 PSUs granted on January 11, 2024, 21,185 have vested as of the date of this Form 4, with the remaining vesting ratably on a quarterly basis over three years thereafter.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of insider transactions, specifically the vesting of equity awards and a subsequent sale of shares to cover tax liabilities, which is a common and expected event for executives. It does not indicate any significant positive or negative operational or financial news for the company.

Positives

• The vesting of Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) indicates the achievement of performance or time-based milestones for the Chief Medical Officer.
• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating a structured and pre-planned approach to equity management rather than a discretionary sale based on immediate market sentiment.

Negatives

• A net reduction of 1,796 shares in direct beneficial ownership (5,327 sold 3,531 acquired) occurred due to the tax-related sale.
• The sale of shares, even for tax purposes, reduces the direct equity stake of a key executive.

Future Outlook

This document, an SEC Form 4, primarily reports past and current insider transactions and does not provide forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This Form 4 filing details routine insider equity transactions for a biopharmaceutical company executive. Such transactions are common across the industry as part of executive compensation and tax planning, and do not typically reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The impact is minor, as the sale is for tax purposes and pre-planned, not indicative of a change in executive confidence. The conversion of PSUs adds shares to the market, but the volume is small relative to total outstanding shares.
• Employees: The vesting of equity awards is a standard component of executive compensation, aligning interests with company performance and retention.

Next Steps

• Remaining Performance Stock Units (PSUs) granted on January 11, 2024, will continue to vest ratably on a quarterly basis over three years.

Key Dates

Keywords

Liquidia Corp, LQDA, Rajeev Saggar, Chief Medical Officer, SEC Form 4, Insider Transaction, Stock Sale, Equity Compensation, Restricted Stock Units, Performance Stock Units, Rule 10b5-1 Plan, Beneficial Ownership